Novo Nordisk shares fell 9% today following news that the weight loss drug CagriSema was not as effective as expected in clinical trials. Investors may not be happy with such news, but on the other hand, this decline can be used to increase the position.
What do you think about this news? Are you buying $NVO after today's drop?
Investors, do you find $LLY or $NVObetter ?
Both companies have very similar businesses and compete with each other. With $NVO, they may be at risk of tariffs that Trump might impose, and their drug may not be as popular in the US. Still, $NVO currently looks more interesting to me , which is why I've been shopping around this year. I think the stock is undervalued and the...
Read more
Now, I think it is impossible to say who is better, because it will only be a few years later. But I'm also buying $NVO right now.
🗓️Klíčové market events of the week: the most important week of the month!
This week is full of interesting macroeconomic data and earnings reports from key companies. Here's a summary of the highlights! 👇
🏠Monday: New home sales!
Let's keep an eye on how the U.S. housing market is doing, which may indicate the health of consumers and the economy as a whole.
📊 Results before the...
Read more
The company is doing well, but I wouldn't buy the stock as it's a pretty volatile and choppy business. You can see it just on this news alone that one drug will fail and the stock will plummet 20%. I think that's terrible.
In the past month alone, $NVOstock is down more than 11%, and according to the Bulios Fair Price Index, the stock is currently slightly undervalued. Recently @edin_medinmentioned this stock , and frankly I'm starting to think about buying it too. If $NVO stock were to drop another 5, 6%, I would buy.
Are you buying $NVOstock on the current decline?
Currently the price is quite low and the price has fallen quite a bit recently, so this could be an interesting opportunity to establish a position.
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
I recently dissected $NVOhere . I decided to buy shares of this company ahead of its earnings. However, this investment did not work out as I expected. After the mediocre results and the US election results, the stock price rose to $116, however, after a short time it plummeted down to $106. Personally, I expected the price to stay at least at the $110 level, which is where I...
Read more
I haven't purchased, but it's a great company from Europe that I think still has a lot of potential with ASML.
The anti-obesity drug industry was in 2023 valued at $5.6 billion and will exhibit a CAGR of 27% between 2024 and 2032 (expert opinion).
$LLY, $NVO and others are creating drugs like - Ozempic, Wegovy, Mounjaro and Zepbound - These are blockbusters in terms of weight loss market in my opinion. But which companies may have the best chance to take the biggest bite of that...
Read more
For me ro are both great companies. I wouldn't be afraid to include them in my portfolio. At what price would you buy $LLY?
📆 Overview of interesting things for the upcoming week! 🚀
This week I will be watching mostly company results. With the investor sentiment from last week, I think wonders will happen when the markets announce earnings.
🔍 Monday:
ISM Services PMI - This index measures economic activity in the service sector and often serves as an indicator of overall economic health.
Earnings: Befor...
Read more
Thanks again for the summary, great! The results will certainly be interesting, but more so in the long run. They can't change the market situation this week in my opinion.
Analysts at Berenberg have raised their estimates for the global obesity market to $150 billion by 2035, up from $125 billion previously. This revision is the result of positive data on co-morbidities and advances in competing studies. Berenberg recommends buying shares of $LLY and Zealand Pharma, while he recommends holding on to shares of $NVO.
What are your thoughts on...
Read more
This sector currently has great potential. However, shares in this sector are already quite expensive. I bought $NVO and I don't regret it.
I've got a smaller position and I'll hold for now. Right now I'm more buying and taking advantage of the downturn in tech stocks.